Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Jan;12 Suppl 1(Suppl 1):s162-3.
doi: 10.2450/2013.0005-13. Epub 2013 Apr 15.

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome

Matteo Molica  1 , Adriano Salaroli  1 , Giuliana Alimena  1 , Massimo Breccia  1
Affiliations
Comment

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome

Matteo Molica et al. Blood Transfus. 2014 Jan.
No abstract available

PubMed Disclaimer

Comment on

  • An update on iron chelation therapy.
    Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. Poggiali E, et al. Blood Transfus. 2012 Oct;10(4):411-22. doi: 10.2450/2012.0008-12. Epub 2012 Jun 27. Blood Transfus. 2012. PMID: 22790257 Free PMC article. Review. No abstract available.

References

    1. Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus. 2012;10:411–22. - PMC - PubMed
    1. Guariglia R, Martorelli MC, Villani O, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as iron chelation therapy: a brief review. Leuk Res. 2011;35:566–70. - PubMed
    1. Breccia M, Loglisci G, Salaroli A, et al. Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to a loss of erythroid response. Acta Haematol. 2010;124:46–8. - PubMed
    1. Breccia M, Finsinger P, Loglisci G, et al. Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population. Ann Hematol. 2012;91:1345–9. - PubMed
    1. Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97:1364–71. - PMC - PubMed